Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.32 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ASPH | Q12797 | 2/20 | 0.32 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | THRA | P10827 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2640736 | 0.76 | RECQL (0.33) | KDM4EPOLBSMN1; SMN2RECQLHCAR2 | |
| SCHEMBL21411394 | 0.66 | GRIN2D (0.34) | PTGS2EHMT2EHMT1KDM4EASPH | |
| SCHEMBL4961428 | 0.65 | LMNA (0.54) | PARP1KDM4EPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL643987 | 0.65 | PARP1 (0.39) | PARP1 | |
| SCHEMBL6037466 | 0.63 | PARP1 (0.38) | PARP1PPARGNCOA2NCOA1RXFP1 | |
| SCHEMBL6644838 | 0.62 | KMT2A (0.57) | KDM4EPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL15340933 | 0.62 | PTGS2 (0.47) | PTGS2KDM4EPOLBSMN1; SMN2 | |
| SCHEMBL29557428 | 0.62 | POLB (0.56) | KDM4EPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL1816768 | 0.62 | POLB (0.56) | KDM4EPOLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL1229534 | 0.61 | ITGA4 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438169-B1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | TOBIRA THERAPEUTICS INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20150344533-A1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | TOBIRA THERAPEUTICS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150247147-A1 | MODULATORS OF COAGULATION FACTORS | TOBIRA THERAPEUTICS, INC. | 2015-09-03 | — | — | US | disclosed |
| US-8889645-B2 | Nucleic acid modulators of glycoprotein VI | REGADO BIOSCIENCES, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889646-B2 | Nucleic acid modulators of glycoprotein VI | REGADO BIOSCIENCES, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8859518-B2 | Modulators of coagulation factors | REGADO BIOSCIENCES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-1745062-B1 | IMPROVED MODULATORS OF COAGULATION FACTORS | REGADO BIOSCIENCES INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20140128587-A1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | REGADO BIOSCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128454-A1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | REGADO BIOSCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| EP-2701746-A2 | A METHOD FOR MANUFACTURING PEGYLATED OLIGONUCLEOTIDES | Regado Biosciences, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| US-7723315-B2 | A nucleic acid ligand whose sequence optionally includes a 2'-O-methyl modification and/or a 2'-O-fluoro modification, useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass | REGADO BIOSCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7531524-B2 | Modulators of coagulation factors with enhanced stability | REGADO BIOSCIENCES, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080153769-A1 | A nucleic acid ligand whose sequence optionally includes a 2'-O-methyl modification and/or a 2'-O-fluoro modification, useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass | TOBIRA THERAPEUTICS, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080125383-A1 | For host undergoing surgery or coronary artery bypass | TOBIRA THERAPEUTICS, INC. | 2008-05-29 | — | — | US | disclosed |
| EP-1745062-A4 | IMPROVED MODULATORS OF COAGULATION FACTORS | REGADO BIOSCIENCES INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-7304041-B2 | Modulators of coagulation factors | REGADO BIOSCIENCES, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070105809-A1 | Modulators of coagulation factors with enhanced stability | REGADO BIOSCIENCES, INC. | 2007-05-10 | — | — | US | disclosed |
| EP-1745062-A2 | IMPROVED MODULATORS OF COAGULATION FACTORS | REGADO BIOSCIENCES, INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060040881-A1 | A nucleic acid ligand whose sequence optionally includes a 2'-O-methyl modification and/or a 2'-O-fluoro modification, useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass. | TOBIRA THERAPEUTICS, INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2005106042-A2 | IMPROVED MODULATORS OF COAGULATION FACTORS | REGADO BIOSCIENCES, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128454-A1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | GP6, DNASE1L3, SELPLG | PARP1 359/4885EGLN1 4181/4885PTGS2 882/4885 |
| US-20150344533-A1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | GP6, DNASE1L3, SELPLG | PARP1 359/4885EGLN1 4181/4885PTGS2 882/4885 |
| US-20080125383-A1 | For host undergoing surgery or coronary artery bypass | NSUN2, SERPINC1, NSUN3 | PARP1 163/4885EGLN1 3714/4885PTGS2 2088/4885 |
| US-20070105809-A1 | Modulators of coagulation factors with enhanced stability | SERPINC1, TFPI, F13B | PARP1 247/4885EGLN1 3391/4885PTGS2 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.